Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash from Financing Activities for 7 consecutive years, with -$32.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 31734.31% to -$32.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$31.7 million, a 237.12% decrease, with the full-year FY2025 number at -$31.7 million, down 237.12% from a year prior.
  • Cash from Financing Activities was -$32.3 million for Q4 2025 at Pliant Therapeutics, down from $72000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $273.3 million in Q1 2023 to a low of -$32.3 million in Q4 2025.
  • A 5-year average of $26.1 million and a median of $498000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 178744.44% in 2023, then tumbled 31734.31% in 2025.
  • Pliant Therapeutics' Cash from Financing Activities stood at $516000.0 in 2021, then plummeted by 44.96% to $284000.0 in 2022, then fell by 22.89% to $219000.0 in 2023, then crashed by 53.42% to $102000.0 in 2024, then crashed by 31734.31% to -$32.3 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Cash from Financing Activities are -$32.3 million (Q4 2025), $72000.0 (Q3 2025), and $498000.0 (Q1 2025).